Core Viewpoint - The company expresses confidence in its development, rooted in the broad prospects of the industry, core competitiveness of its business, and efficient governance system [2] Group 1: Business Segments - The company's main business operations include building materials manufacturing, biopharmaceutical research and production, and private equity fund management [2] - The company aims to actively promote the development of its biopharmaceutical business while solidifying its existing operations [2] Group 2: Industry Opportunities - The global pharmaceutical industry is currently in a strategic opportunity period driven by innovation, with a clear long-term stable growth outlook [2] - The venture capital funds invested by the company further expand its strategic layout in emerging fields such as biotechnology [2] Group 3: Competitive Advantages - The biopharmaceutical business possesses deep technical accumulation, stable core product layout, leading production capacity, and comprehensive service capabilities [2] - The core team has rich industry experience, continuously consolidating competitive advantages [2] Group 4: Private Equity Management - The private equity fund management business relies on a specialized investment team, a complete investment management system, and a mature post-investment management system, forming a systematic and comprehensive investment management capability [2] Group 5: Governance and Future Outlook - The company has a sound and standardized governance structure, with efficient decision-making and effective supervision, providing a solid guarantee for business development [2] - The company will continue to focus on its core business, fully seize industry opportunities, and steadily improve operating performance to create more value for all shareholders [2]